Ovarian Germ Cell Tumors

Ovarian germ cell tumors are tested on USMLE Step 1 primarily through tumor marker matching and the mature vs. immature teratoma distinction — and the reliable trap is assigning AFP to dysgerminoma when AFP belongs to yolk sac tumor. These neoplasms derive from primordial germ cells and span a wide spectrum: from the completely benign mature cystic teratoma (dermoid cyst) to aggressive malignancies like yolk sac tumor and dysgerminoma. The exam hits two main angles: teratoma pathology (mature vs. immature, and struma ovarii) and matching each malignant germ cell tumor to its correct marker. Expect vignettes describing a young woman with a pelvic mass, an ultrasound finding hair and teeth, or a lab result — your job is to identify the tumor type and its clinical implication.

The tricky part is that students often mix up the tumor markers. AFP, beta-hCG, and LDH all come up in this category, and the exam exploits the fact that students conflate which marker belongs to which tumor. Dysgerminoma is the most commonly tested malignant germ cell tumor, and its marker profile (LDH, beta-hCG) surprises people who assume AFP is the go-to marker for all germ cell tumors. Meanwhile, AFP is the hallmark of yolk sac tumor — not teratoma — a distinction USMLE Step 1 tests directly.

The other classic trap is calling the mature cystic teratoma malignant because it contains such a wild mix of tissues (hair, teeth, sebaceous material, thyroid tissue). That heterogeneity is actually the definition of a mature teratoma — fully differentiated tissue from all three germ layers — and it is benign. The malignant counterpart is the immature teratoma, characterized specifically by immature neuroepithelium. Get these distinctions locked in and this topic becomes very manageable.